These two stocks weathered the March crash without incident.
News & Analysis: Emergent BioSolutions
The expert in bioterrorism and emerging infectious diseases had a great second quarter, with more to come.
EBS earnings call for the period ending June 30, 2020.
There could be an even larger contract coming if the vaccine to prevent COVID-19 is successful.
Emergent’s contract manufacturing capabilities make it a much-desired collaborator in the race for a coronavirus vaccine.
Both of these companies could play a huge role in ending the COVID-19 pandemic.
This biotech has emerged as the manufacturing partner of choice for companies developing COVID-19 vaccines.
Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.
Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.
Which stock wins in a battle between a COVID-19 testing leader and the top contract manufacturer for COVID-19 vaccines?